bioAffinity Technologies (BIAF) Operating Expenses (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Operating Expenses for 6 consecutive years, with $928636.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 79.27% year-over-year to $928636.0; the TTM figure through Mar 2026 stood at $13.2 million (down 28.53% YoY), while the FY2025 annual figure was $16.7 million, down 8.63% from the prior year.
• Operating Expenses retreated to $928636.0 in Q1 2026 per BIAF's latest filing, from $4.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $5.2 million in Q4 2024 and bottomed at $685279.0 in Q2 2022.
• Historically, Operating Expenses has averaged $3.0 million across 5 years, with a median of $3.7 million in 2025.
• Annual changes were most pronounced in 2023 — Operating Expenses jumped 180.12% — and 2026, when it sank 79.27%.
• bioAffinity Technologies' Operating Expenses stood at $1.6 million in 2022, then surged by 180.12% to $4.6 million in 2023, then gained by 13.13% to $5.2 million in 2024, then slipped by 8.23% to $4.7 million in 2025, then plunged by 80.37% to $928636.0 in 2026.
• Business Quant data shows BIAF's Operating Expenses at $928636.0 in Q1 2026, $4.7 million in Q4 2025, and $3.7 million in Q3 2025.